Miami Hematology Oncology Program Director shared a post on X:
“As a center of excellence for Sarcoma and a major referral center, we included a dedicated Sarcoma 101 session in our Fellowship Bootcamp, led by Steve Bialick (Sylvester Comprehensive Cancer Center).
Key highlights from this high-yield session:
Biology and Genetics:
- Mesenchymal origin – bone, cartilage, muscle, fat, connective tissue.
- Genetic syndromes: Li-Fraumeni (TP53), Retinoblastoma (RB1), NF1/NF2, FAP (APC), Carney-Stratakis (KIT/PDGFRA).
- Molecular drivers: KIT, PDGFR, RAF, MDM2, EWS-FLI1, SS18-SSX, INI1 loss.
Treatment Evolution:
- Backbone chemo: Doxorubicin ± Ifosfamide.
- Subtype-specific: Gem/Docetaxel (LMS), Vincristine/Irinotecan (Ewing’s), Paclitaxel (Angiosarcoma).
- New FDA approvals since 2020: Nirogacestat, Atezolizumab, nab-Sirolimus, Crizotinib, Tazemetostat, Avapritinib, Ripretinib.
- Precision is key: Molecular profiling is essential – just say YES to NGS!”
More posts featuring Miami Hematology Oncology Program Director.
